Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Boston Scientific's Voraxaze's MAA Accepted by EMA for Review

Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

Investors continue to be upbeat about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.

Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes

Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.

EPA Validates NEOGEN's Disinfectant for Use Against COVID-19

NEOGEN's (NEOG) BioSentry 904 Disinfectant approved by the EPA for use against the COVID-19-causing SARS-CoV-2 virus.

Omnicell, Pharmaceutical Strategies Enter Acquisition Deal

Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.

Sweta Killa headshot

5 Top-Ranked Dividend Growth Stocks Still At Bargain Prices

Stocks that have a strong history of dividend growth, as opposed to those that offer high yields, form a healthy portfolio with more scope for capital appreciation.

Here's Why You Should Hold on to Intuitive Surgical Stock Now

Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.

Baxter (BAX) Receives EUA for Regiocit Replacement Solution

Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.

Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected (Revised)

Cardiovascular Systems (CSII) registers significant decline in STEMI activations in Q4 earnings as patients avoid hospitals.

Myriad Genetics' (MYGN) Q4 Loss Narrower Than Estimated

Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.

Here's Why You Should Hold on to Stryker (SYK) Stock Now

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.

Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates

Accuray (ARAY) registered decline in Product and Service revenues in Q4

Medtronic (MDT) Plans $160 Million R&D Investment in India

The newest expansion plan of MEIC will help Medtronic (MDT) advance in the field of pain alleviation and restoration of health.

HMS Holdings (HMSY) Loses 2.9% Since Q2 Earnings Release

HMS Holdings (HMSY) witnessed revenue growth in COB segment in Q2.

Medtronic Plans New Acquisition in AI-Driven Diabetes Care

Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.

Change Healthcare (CHNG) Gains 1.9% Since Q1 Earnings Beat

Change Healthcare's (CHNG) fiscal first-quarter results benefit from solid performance across the Network Solutions segment and lower operating expenses.

Chemed's (CHE) VITAS Business Strong Amid Coronavirus Crisis

Amid the pandemic scenario, Chemed's (CHE) VITAS and Roto-Rooter both have been classified as essential services.

National Vision (EYE) Stock on the Rise Since Q2 Earnings Beat

Investors seem to be impressed with National Vision's (EYE) better-than-expected second-quarter 2020 results despite the coronavirus-led economic crisis.

AMN Healthcare (AMN) Loses 3.3% Despite Q2 Earnings Beat

AMN Healthcare (AMN) gained from two of its three core operating segments in Q2.

Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat

Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.

Syneos Health (SYNH) Q2 Earnings Top Estimates, Margins Down

Syneos Health (SYNH) wins 35 COVID-19 related projects through the second quarter.

PRA Health (PRAH) Q2 Earnings and Revenues Beat Estimates

PRA Health's (PRAH) Data Solutions segment puts up a strong performance in Q2.

Integra (IART) Q2 Earnings Surpass Estimates, Margins Fall

Integra's (IART) second-quarter 2020 results reflect disappointing segmental performance due to coronavirus-led business disruptions.

Insulet (PODD) Q2 Earnings Beat Estimates, 2020 View Up

Insulet's (PODD) total Omnipod product line comes up with record revenue growth.

Globus Medical (GMED) Beats Q2 Earnings & Revenue Estimates

Globus Medical (GMED) witnesses dismal segmental and international performance in the second quarter owing to pandemic-led adversities.